News | September 14, 2011

GE Launches Company to Enhance Development of Innovative Imaging Technology

September 14, 2011 – To accelerate and enhance the development of metabolic imaging and other innovative technology, GE has launched a new entity, Research Circle Technology Inc. (RCT). RCT’s vision is to create a strong alliance between GE’s scientists and the world’s leading universities, providing easy access to GE’s organic technology and wide scope of healthcare expertise in an open innovation structure.

Already, global leaders of imaging technology and disease detection research have explored potential applications for metabolic imaging technology:

  • University of California – San Francisco’s Surbeck Laboratory for Advanced Imaging has announced the groundbreaking results of a study utilizing GE’s 13-C (Carbon 13) technology to study prostate cancer. “This is the first time researchers have used this technology to conduct real-time metabolic imaging in a human patient, and represents a revolutionary approach to assessing the precise outlines of a tumor, its response to treatment and how quickly it is growing,” said Sarah J. Nelson, Ph.D., a professor of radiology and biomedical imaging at UCSF. Nelson is presenting the team’s findings at the World Molecular Imaging Conference (WMIC) in San Diego this week.
  • Scientists at Cancer Research UK’s Cambridge Research Institute have developed a technique to show the effectiveness of breast cancer treatment weeks earlier than current methods through metabolic imaging. According to lead researcher Professor Kevin Brindle, “There has been a need to develop imaging methods that can help detect treatment response more accurately than traditional methods and before tumors change size. Our new imaging method not only shows early evidence that treatment is working but could also help predict the long-term outcome. We expect that these techniques will have an impact for patients in the near future.”

Through RCT, GE looks to continue developing this innovative technology, providing the tools, services and solutions so that leading researchers can focus on their investigations into the biochemistry of metabolism and speed the discovery of potentially lifesaving knowledge. RCT will sell SpinLab polarizers as well as provide the licensing framework for partners to continue to develop the metabolic imaging applications. RCT helps enable GE to fully connect with the skills and knowledge of the research community, with the goal of transitioning technology from ‘bench to bedside’ more efficiently.

“The focused goal of RCT is open collaboration to bring hyperpolarization technology to the worlds’ leading researchers and enable their studies to better understand the biochemistry of life,” said Jonathan A. Murray, managing director, RCT. “The early results are very exciting and we are delighted to collaborate with this community to help bring this innovative technology to its full potential.”

For more information: www.gehealthcare.com

 

Related Content

SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
Overlay Init